|
Q2 FY2026
As of Jul 3, 2026
|
Q1 FY2026
As of Apr 3, 2026
|
Q4 FY2025
As of Jan 2, 2026
|
Q3 FY2025
As of Oct 3, 2025
|
Q2 FY2025
As of Jul 4, 2025
|
Q1 FY2025
As of Apr 4, 2025
|
Q4 FY2024
As of Jan 3, 2025
|
Q3 FY2024
As of Sep 27, 2024
|
Q2 FY2024
As of Jun 28, 2024
|
Q1 FY2024
As of Mar 29, 2024
|
Q4 FY2023
As of Dec 29, 2023
|
Q3 FY2023
As of Sep 29, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 30, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jul 1, 2022
|
Q1 FY2022
As of Apr 1, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Oct 1, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Receivables, net | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued payroll and employee benefits | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, net of current portion | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized and no shares issued and outstanding at January 2, 2026 and January 3, 2025 | ||||||||||||||||||||
| Common stock, $0.0001 par value, 500,000,000 shares authorized, 125,492,013 and 126,380,657 shares issued and outstanding at July 3, 2026, and January 2, 2026, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Leidos stockholders’ equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
